Ecuador Medical Device Registration: 28 ARCSA FAQs on Classification, Fees and Timelines (2026)

Summary: official fees of approximately USD 904 per imported product, registrations valid for 5 years, settlement fully in US dollars with no exchange rate risk, and – once the new regulation takes effect on 28 January 2027 – a simplified 30 business day registration pathway for products holding FDA/CE approval. Ecuador may be the most underrated one-stop entry point for Chinese devices into the Andean market. The following 28 questions and answers cover classification, pathways, fees, holder structures, customs clearance and post-market compliance.

Ecuador is one of the few fully dollarized economies in Latin America (since 2000), with a population of approximately 18 million. Its public health system runs on two tracks – the Ministry of Public Health (MSP) and the social security institute (IESS) – and centralized public procurement (SERCOP) is the largest volume channel for medical devices. Third-party market research data put the medical device market at approximately USD 839 million in 2024, with a projected compound annual growth rate of approximately 6.4% for 2024-2028 (industry estimate, Statista basis).

The market has long depended on imports, and the installed base of Chinese supply runs deeper than most people assume. Third-party statistics on the public ARCSA registration database (June 2026 snapshot) show approximately 326,000 product records in total, 22,056 valid sanitary registrations and 2,238 registration holders; records identifiable by brand as Chinese manufacturers number approximately 9,281 (Mindray 2,321, Hanhai 2,197, Snibe 2,101, Chunli 1,424 and others), about 2.8% of the database. In addition, large volumes of Chinese OEM output are registered under local agents’ own brands (private label), so the actual manufacturing share is estimated by the industry at more than 8%-10%.

On institutional cost, Ecuadorian registration fees are denominated directly in US dollars (approximately USD 904.34 per imported product), registrations are valid for 5 years, and as a member of the Andean Community (CAN) Ecuador applies a four-class classification aligned with IMDRF – manufacturers with existing CE/FDA/Australian evidence can obtain significant acceleration. More importantly, the new regulation signed on 28 April 2026 (Resolucion ARCSA-DE-2026-003-DASP) will take effect on 28 January 2027 and introduces, for the first time, a simplified pathway recognizing registrations from IMDRF high-regulation authorities, compressing eligible reviews to 30 business days.

This article lays out the full picture of Ecuadorian registration through 28 questions and answers. All key conclusions have been verified against official sources: regulation texts, WTO notifications, Official Gazette milestones, ARCSA database statistics and others.

1. Market and regulatory framework

Q1. Is the Ecuadorian market worth entering?

Yes – and it suits Chinese manufacturers as a “dollar safe haven” for their Andean footprint. There are four reasons:

• Market fundamentals: population of approximately 18 million, fully dollarized settlement, public procurement (SERCOP) driving volume; third-party market research estimates the device market at approximately USD 839 million (2024) with a compound annual growth rate of approximately 6.4% (industry estimate).
• Import dependence: domestic manufacturing capacity is limited, the vast majority of devices are imported, and 63% of the registration database consists of invasive products (mainly orthopaedics, trauma and interventional) – a high overlap with the strengths of the Chinese supply chain.
• Chinese installed base: approximately 9,281 registration records identifiable as Chinese brands (2.8% of the database); adding OEM/private-label registrations, the actual manufacturing share is estimated by the industry at more than 8%-10%. Channels and supply chains have been validated.
• Institutional cost: fees in US dollars (approximately USD 904 per product), registrations valid for 5 years, no exchange rate conversion loss; the total cost of holding is low among major Latin American markets.

Q2. Who is the regulator?

ARCSA (Agencia Nacional de Regulacion, Control y Vigilancia Sanitaria – the National Agency for Health Regulation, Control and Surveillance), under the Ministry of Public Health (MSP), is responsible for the sanitary registration (Registro Sanitario) of medical devices for human use, import control and post-market surveillance.

Establishment history: ARCSA was created by Decreto Ejecutivo No. 1290 (signed 2012-08-30, Official Gazette Supplement No. 788, 2012-09-13), replacing the former National Institute of Hygiene and Tropical Medicine (INH “Dr. Leopoldo Izquieta Perez”), and was amended by Decreto 544 in 2015. It is headquartered in Guayaquil, with offices in Quito, Cuenca and other cities. Its remit covers drugs, biologics, medical devices, in vitro diagnostics, dental products and sanitary operation of premises. Its website is controlsanitario.gob.ec, and its registration database (catastro de dispositivos medicos) is open to the public.

Q3. Which documents make up the core regulatory framework?

Practical note: Ecuador’s regulatory amendment chain appears in both the Official Gazette and WTO notifications (the two resolution numbers 026-2016 and 033-2017 both point to the same institutional framework consolidated between 2016 and 2018). Which provisions ultimately apply is determined by the official text in the Registro Oficial; for compliance assessments, cross-check the original gazette texts together with ARCSA’s operating guidance.

Q4. How large is the registration database, and where do Chinese manufacturers stand?

Third-party statistics on the public ARCSA database (snapshot of 2026-06-21) show:

Where Chinese manufacturers stand: records identifiable by brand total approximately 9,281 (Mindray 2,321, Hanhai 2,197, Snibe 2,101, Chunli 1,424, Maccura 475, Edan 434, Wondfo 118, Yuwell 111, among others). Adding OEM/private-label registrations, the actual manufacturing share is estimated by the industry at more than 8%-10%. Annual certificate issuances grew from 9,402 in 2011 to 37,972 in 2025 – a 4.04-fold increase over 14 years – so the market is in a period of rapid expansion.

Q5. How does Ecuador differ institutionally from Colombia, Chile and Brazil?

This is where errors are most common, so the conclusion first: Ecuador uses a four-class system, I/II/III/IV, and does have a Class IV; Colombia uses I/IIa/IIb/III and has no Class IV. Some Chinese-language sources misapply Colombia’s classification to Ecuador; using the wrong system in a tender or when assigning a class leads directly to rework of the documentation.

Common ground with Brazil’s ANVISA: both have a Class IV (highest risk, e.g. implants in direct contact with the heart or central nervous system), and IVDs in both follow separate classification rules. The biggest difference from Colombia: dollarized settlement plus 5-year validity – the payment terms and cost-of-holding models are completely different, so budget for Andean multi-country programs separately.

2. Product classification and registration pathways

Q6. How are products classified?

A four-class risk classification applies: Class I (low risk), Class II (medium risk), Class III (high risk) and Class IV (very high risk), aligned with the IMDRF framework. The classification rules are set out in the “Reglamento y Control Sanitario de Dispositivos Medicos y Dentales” (2009), Article 16 (devices) and Article 23 (diagnostic products). The core determining factors include:

Typical examples: Class I (bandages, examination gloves, manual instruments, hospital beds); Class II (injection needles, sutures, blood pressure monitors); Class III (orthopaedic implants, dialysis equipment, ventilators, infusion pumps, intraocular lenses); Class IV (cardiovascular stents, pacemakers, heart valves, drug-device combinations). Where several rules conflict, the highest class applies.

Practical note: Ecuadorian classification shares its origins with Australia’s TGA and Brazil’s ANVISA – manufacturers with classification conclusions for either market can use them as a high-confidence starting point for Ecuador. For borderline products (at the Class II/III boundary), pre-confirmation with ARCSA through a local authorized representative is recommended to avoid months of rework.

Q7. What rules apply to IVDs, software and customized products?

• IVDs: they share the same four classes I-IV as devices, but apply the independent classification rules of Article 23. Determining factors include self-testing, near-patient testing (POCT), companion diagnostics, screening of blood or tissues, and detection of highly transmissible infectious pathogens. ARCSA manages IVDs through a subcatalogue: analytical performance validation data (cross-reactivity, stability, etc.) must be submitted, and reagents for high-risk infectious disease screening must be re-checked by the national reference laboratory INSPI.
• SaMD (software as a medical device): the new regulation defines it for the first time and classifies it under the IMDRF/N12 risk matrix; devices containing AI/ML algorithms are brought under regulation for the first time (per public interpretations, involving algorithm transparency, training data validation and performance monitoring documentation).
• RUO (research use only) products: the new regulation brings them within the regulatory definitions for the first time; manufacturers exporting products labelled “research use only” need to re-evaluate their compliance pathway.
• Devices containing human or animal cells or tissues: joint Resolution RI No. 001-INDOT-ARCSA-2025 divides responsibilities between INDOT and ARCSA (INDOT governs cells and tissues; ARCSA governs devices containing biological components).

Q8. What registration pathways are available?

There are two sets, current and future. Conclusion first: file now under the current framework (standard registration plus simplified registration for Class I/II); file from 2027-01-28 under the new regulation (standard registration plus an IMDRF-recognized simplified pathway covering all classes).

Current framework (until 2027-01-28):

1. Standard registration: applies to all classes, with documentation requirements tiered by risk class;

2. Simplified registration (introduced by Resolution ARCSA-DE-030-2018-JCGO in 2018): Class I/II products already registered in one of the United States, the European Union, Canada, Australia, Japan or South Korea may take the simplified review route – per industry feedback, the timeline can be compressed from 4-6 months to 2-3 months.

New regulation (from 2027-01-28):

3. Standard registration: all classes, with fully detailed technical documentation requirements;

4. Simplified registration (Articles 31-32): ARCSA recognizes registrations or equivalent documents issued by IMDRF high-regulation member authorities (FDA, EMA, Health Canada, TGA, ANVISA, etc.), covering all classes I-IV; up to 100 models per application (50 for Class IV); kits and combinations may share a single registration (classified by the highest-risk member, with expiry set by the shortest validity); assessment period of 30 business days (excluding applicant correction time).

Key insight: simplified does not mean exempt from registration. Under both pathways, the obligations for a local Titular, premises permits and good practices (BPADT) are unchanged – the readiness of partners and facilities is often the real bottleneck in the timeline.

Q9. What does the 2026 new regulation change, and when does it take effect?

Resolucion ARCSA-DE-2026-003-DASP (the “Alternative Technical Health Regulation for the Sanitary Registration, Control and Surveillance of Medical Devices for Human Use”) was signed by ARCSA Executive Director Daniel Antonio Sanchez Procel on 2026-04-28, published in the Official Gazette on 2026-05-18, and takes effect 9 months after signing, i.e. on 2027-01-28. Milestones: the draft was notified on 2025-10-29 through the WTO ePing platform and the Andean Community SIRT platform (60-day comment period), and on 2026-05-26 Ecuador confirmed the effective date through the WTO addendum (G/TBT/N/ECU/325/Add.5).

Core changes:

Transition for existing registrations (per public interpretation): products already registered remain valid until natural expiry; renewals after expiry, and new registration applications, follow the new framework. Filings under the current regulation continue to be governed by it – applications submitted before the new regulation takes effect do not lapse because of the change.

Practical note: October 2026 to January 2027 is a “dual-track window”. Manufacturers holding FDA/CE evidence can weigh waiting about 3 months for the 30-business-day simplified route against locking in Class III/IV standard registration under the current framework now (see Q27).

Q10. Can low-risk products skip registration?

Under the current system, all devices (including Class I) must obtain a registration certificate before they can be imported and sold. Public interpretations of the new regulation mention that “low-risk products may be commercialized freely provided basic sanitary requirements are met”, but the exact boundary (which products, what obligations) awaits ARCSA’s implementing guidance – this point is flagged as to be verified, and current filings should still proceed on the basis that everything must be registered.

3. Timelines, official fees and import costs

Q11. What are the official review timelines and the actual timelines?

Planning recommendation first: budget 4-8 months, and use the upper end for Class III/IV.

• Commonly observed industry timelines: 2-6 months (consistent across multiple sources including MDRC); 6-12 months for high-risk products;
• Accelerating effect of CE/FDA: approximately 2-3 months on the simplified route (versus 4-6 months on the standard route);
• Simplified route under the new regulation: assessment period of 30 business days (excluding correction round-trips);
• Conservative service-provider estimates: 7-14 months.

The statutory review timeline for the standard route after the new regulation takes effect will be set by the operating guidance ARCSA publishes alongside it (to be verified). The deficiency (requerimiento) mechanism also exists under the current framework; each round typically adds 1-3 months – getting the dossier right the first time is worth more than any “expediting”.

Q12. What are the official fees?

The sanitary registration fee for imported products is approximately USD 904.34 per product – figures cited by multiple industry bodies are highly consistent. Local products cost approximately USD 678.25; variations approximately USD 95; renewals approximately USD 185.

Q13. How are import taxes structured?

The tax burden at customs has four layers. Conclusion first: medical devices enjoy no general VAT exemption, so assess by the specific HS code.

The China-Ecuador FTA is the biggest cost variable: the free trade agreement between China and Ecuador was signed on 2023-05-11 and entered into force on 2024-05-01 (China’s 20th FTA and Ecuador’s first with an Asian country). Both sides will progressively eliminate tariffs on approximately 90% of tariff lines, with approximately 60% going to zero on the day of entry into force; machinery and electrical equipment, among China’s main export categories, are included. Making good use of the rules of origin (certificates of Chinese origin) can substantially reduce the ad valorem tariff.

Q14. What is the total turnkey cost?

The official fee is only a fraction. The industry-estimated composition of the total turnkey cost for one imported product is: official fee of approximately USD 904, plus translation, notarization and apostille, plus local holder/agent service fees, plus possible testing and travel. Service providers publicly quote service fees of USD 3,000-6,000 per project for Ecuador, with timelines assessed specifically by product class.

Strategy recommendation: for product lines with many models (especially IVD reagent families and implants with many sizes), evaluate “one certificate, many models” first – under the current system a single registration can cover a series of models from the same manufacturer, spreading the USD 904 marginal official fee across dozens of models. Budget in US dollars per Q12; no buffer for exchange rate fluctuations is needed.

4. Local registration holder, importer and submission dossier

Q15. Why must foreign manufacturers appoint a local Titular?

Because foreign manufacturers cannot apply to ARCSA directly. Ecuador operates a registration holder (Titular del Registro Sanitario) system:

• The applicant (solicitante) must be a locally established entity legally registered in Ecuador, holding a RUC tax number and a valid ARCSA operating permit (permiso de funcionamiento);
• The Titular named on the registration certificate is in practice this local entity (importer/agent), while the foreign manufacturer acts as the fabricante issuing a letter of authorization (POA, apostilled or consularly legalized and translated into Spanish);
• The application is submitted through the VUE/ECUAPASS portal and requires two electronic signatures (TOKEN) – the legal representative and the pharmaceutical/technical responsible person;
• Industry database analyses state explicitly: Chinese manufacturers cannot act as the Titular directly; a local entity (subsidiary or partner) must hold the registration.

Q16. What are the pitfalls in choosing a Titular?

Registration rights equal channel rights – this is the single largest commercial risk point of the Ecuadorian system for Chinese manufacturers.

Of the 22,056 registrations in the database, 2,238 are held by 2,238 holders, and the TOP 20 hold approximately 39.3%. The top holders include multinational self-operated entities such as B. Braun and Roche, large distributors such as SIMED, TRAUMA ORTOPEDICS and ORMEDIC, and pure compliance holding platforms such as REGULATEC (which is not itself a distributor). Choosing a Titular is in essence choosing “regulatory agency capability”, not merely a channel.

The pitfall lies in exit: per industry practice, a change of holder (cesion/modificacion) is a minor variation that does not require re-registration, but if the original holder refuses to cooperate in signing the transfer declaration, in practice there is usually no option but to submit a completely new registration – a new clock and new fees. If the agency contract does not hard-code the exit terms, the brand stays “locked” onto the registration certificate.

Four clauses every contract must contain: (1) ownership of the registration certificate belongs to the manufacturer; (2) unconditional cooperation in signing the transfer declaration within 30 days after the agreement terminates; (3) access rights to the dossier and registration data; (4) responsibilities for adverse event reporting and safety response. A more thorough approach is a neutral registration-holding structure – the registration then does not move when the distributor changes.

Q17. How should the certificate of free sale (CFS) be prepared?

• Source: a certificate of free sale issued by the competent authority of the country of origin; or a free sale certificate from one of the six reference jurisdictions – the United States, Canada, Australia, Japan, the European Union or South Korea (recognized under the current framework);
• Authentication chain: apostille or consular legalization plus Spanish translation. China has been a party to the Apostille Convention since 7 November 2023 and can obtain the apostille directly, with no consular legalization required;
• Facilitation under the new regulation: electronic official documents whose authenticity can be verified online may be exempt from legalization;
• Content: the certificate must list the full set of models to be registered (corresponding one to one with the registration application);
• Validity: CFS documents have validity requirements, and expiry is one of the most frequent causes of deficiency notices – apply for it close to the submission date.

Q18. What exactly does the technical dossier require?

It divides into legal documents and technical documents, with some requirements in Spanish:

Legal documents (all requiring notarization/apostille):

Application form, operating permit of the local applicant, list of devices to be registered, fee payment receipt, manufacturer’s letter of authorization (POA), CFS, and the GMP certificate from the country of origin or an ISO 13485 certificate from a recognized body.

Technical documents:

Quality report and sterility report (signed, with name and title), finished product specifications, product description (functional components/structure/drawings), description of raw materials, stability report, explanation of lot numbering rules, Spanish labels and IFU (Spanish is mandatory for professional-use devices as well), inner and outer packaging specifications, manufacturing process and flowchart, biological function report, IEC 60601 (where applicable), ISO 10993 biocompatibility (where applicable), scientific evaluation, HS code, and GMDN/ECRI generic names.

The new regulation further details the requirements for components, raw materials, processes, stability, sterility certificates, clinical research and IVD performance studies. The HS code must be declared at registration – it is advisable to have the local authorized representative help determine it, as it also determines the customs tax burden (Q13).

Practical note: the Ecuadorian database has no country-of-origin field, so competitive and compliance analysis can only proceed by reverse matching on brand. For Chinese manufacturers, a solid mapping between GMDN/ECRI generic names and brand names is the prerequisite for being “findable” in the local database.

Q19. What quality system is required? Is ISO 13485 enough?

Either a GMP certificate issued by the health authority of the country of origin or an ISO 13485 certificate issued by a recognized body is sufficient (all copies must be notarized). In practice, ISO 13485:2016 is the most commonly used evidence, and the certificate’s scope must cover the manufacturer and products within the scope of registration.

New addition under the new regulation: the ISO 13485 certificates of local device manufacturing laboratories and IVD reagent manufacturers must be registered with ARCSA (issued by conformity assessment bodies accredited by SAE or designated under MPCEI) – purely export-oriented Chinese manufacturers are not affected, but the requirement applies if production is set up in Ecuador.

Also note: Ecuador is not within MDSAP coverage, so an MDSAP certificate cannot substitute for ARCSA registration; CE/FDA certificates do not constitute an automatic conversion, but they have clear value as support for the simplified pathway and for review (Q8, Q20).

5. Clinical evidence and post-market compliance

Q20. What clinical evidence is required?

Requirements are tiered by class; IVDs emphasize performance data, and Class III/IV emphasize safety and effectiveness evidence. CE/FDA documents are the most reliable “acceleration lever” but do not exempt from registration.

• Class I/II: technical reasoning, literature or equivalence evidence is usually sufficient;
• Class III: relatively complete safety and effectiveness data are required, including risk management, a list of applicable standards and clinical use data;
• Class IV: the strictest requirements – per public interpretations of the new regulation, the highest-risk products (e.g. implants retained in the body for more than 30 days) must meet higher standards including biocompatibility, clinical investigation and real-world performance evidence;
• IVDs: analytical performance validation (cross-reactivity, stability, etc.) is the core; reagents for high-risk infectious disease screening are re-checked by INSPI;
• Role of CE/FDA: as supporting documents they substantially simplify review and shorten timelines (approximately 2-3 months with international certificates versus 4-6 months), and significantly reduce the probability of deficiency notices;
• Local clinical trials are not a routine prerequisite: registration can be completed without local clinical data; if clinical trials are conducted in Ecuador, they require ethics committee and regulatory approval.

Q21. How long is a registration valid, and how is it renewed?

Five years, renewable for an equal period (identical under the current system and the new regulation).

• Renewal window: current practice is at least 90 days before expiry; the new regulation specifies filing at least 90 business days before expiry and no earlier than 6 months;
• Renewal fee: approximately USD 185 (industry-cited);
• Renewal peak warning: by the expiry distribution in the database, approximately 47,853 records expire in 2026, 37,566 in 2027, 69,208 in 2028, 58,611 in 2029 and 60,359 in 2030 – more than 270,000 records enter their renewal cycles across 2026-2030, and renewals must follow the new regulation’s IMDRF classification and updated documentation requirements;
• Consequence of lateness: missing the window means the application is treated as new – new clock, new fees.

Strategy recommendation: set the renewal starting point at 6 months before expiry, not 90 days. The renewal wave will strain review capacity, and adapting dossiers to the new framework (classification alignment, detailed documentation) itself takes 2-3 months of preparation.

Q22. What adverse event and post-market obligations apply?

Conclusion first: the new regulation turns post-market compliance from a “gray zone” into enforceable hard obligations, with penalties anchored directly in the Ley Organica de Salud (Ley 67/2006).

• Mandatory technovigilance (Tecnovigilancia): reporting through the national technovigilance system – serious adverse events (death, life-threatening situations, hospitalization, disability, medical or surgical intervention), field safety corrective actions (FSCA, including recalls), and near-miss events; specific reporting deadlines follow the rules of the national technovigilance system (to be verified);
• Two-tier post-registration control: tier one is visual inspection (labels, packaging, storage conditions, documents); tier two is laboratory testing (covering technical specifications, biocompatibility, sterility assurance, electrical safety, and even software functions and cybersecurity);
• Traceability: GS1 barcodes with lot-level traceability across the entire manufacture-distribution-use chain;
• Penalties: product seizure, suspension or cancellation of registration, fines, import prohibition; serious cases (fraud or deliberate concealment) involve criminal liability;
• Enforcement example: in May 2025, ARCSA sealed two premises in Cuenca and seized approximately 49,000 devices without sanitary registrations (including brain spatulas, tumor forceps, skin separators and ophthalmic cannulas); the products were immobilized until compliance was restored, and the authority simultaneously reminded suppliers that a valid BPADT (good storage/distribution/transport practices certificate) is required.

Practical note: before signing with a local holder, ask one question – “who executes the 72-hour/same-day response to serious events, and how?” A holder without local response capability exposes the manufacturer to penalties under the Ley Organica de Salud.

Q23. What if the product information needs to change?

• Variation versus re-registration: ordinary changes go through the variation procedure (modificacion, official fee approximately USD 95); major changes affecting safety and effectiveness (significant changes in design, chemical composition or intended use) require re-registration;
• Final label obligation: within 1 year after the certificate is granted and before commercialization, the final label bearing the registration number must be submitted to ARCSA (NDM017); the same applies to subsequent updates of the final label;
• Voluntary cancellation: the holder may apply to cancel the registration voluntarily, free of charge, submitting the holder’s appointment documents and a market withdrawal strategy;
• Domestic labelling/conditioning (new regulation): imported devices may be labelled/conditioned within Ecuador to meet registration requirements – the site must hold GMP or ISO 13485 registered with ARCSA (labelling-only sites may hold BPADT), and the process must not affect product stability or primary packaging integrity.

6. Import clearance, special scenarios and market entry strategy

Q24. How does import clearance work once the registration is granted?

Two tracks run in parallel, conclusion first: ARCSA sanitary release and SENAE customs clearance are separate lines – clearing one does not mean clearing the other.

1. VUE/ECUAPASS filing: the importer applies through the foreign trade single window (ECUAPASS-VUE), having first registered with SENAE as an importer and holding a valid RUC;

2. ARCSA release: sanitary control clearance (visto bueno) is obtained against a valid registration certificate;

3. SENAE clearance: the customs declaration (DAI) is routed by risk to inspection channels – three tiers of physical inspection (aforo): automatic release, document review, physical inspection;

4. Label verification: the outer packaging must state the Titular’s name, RUC and registration number in Spanish; customs cross-checks the bill of lading against the packaging, and mismatches lead to detention and administrative fines;

5. Storage and distribution: the holder’s warehousing/distribution/transport requires a valid BPADT (Resolucion ARCSA-DE-2024-047-DASP, effective June 2025).

Q25. What are the barriers to public procurement?

SERCOP (the official public procurement system, compraspublicas.gob.ec) is the largest volume channel for devices in Ecuador. Its hard thresholds: bid products must hold a valid ARCSA sanitary registration number, and the Titular must have the corresponding qualifications (including BPADT). The public market weights price heavily and prices of some products are controlled; dollar settlement removes exchange rate risk, but it also means there is no price buffer from local currency depreciation – quotation models must be calculated precisely as “landed full cost plus the four tax layers (Q13)”. Some products (such as assistive devices for persons with disabilities) enjoy foreign trade tax exemptions under specific conditions, determined by the specific HS code and use.

Q26. How are special product scenarios handled?

Q27. File now or wait for the new regulation? How should the timing trade-off be read?

Conclusion: decide by product category, and build the dossier now to a “reusable evidence” standard.

• Class I-IV products already registered with IMDRF high-regulation authorities (FDA/CE/ANVISA, etc.): it is worth evaluating waiting for the simplified pathway after 2027-01-28 – a 30 business day assessment period is far faster than any current route; if the business cannot wait about 3 months, the simplified route for Class I/II under the current framework (registrations in the US, EU, Canada, Australia, Japan or South Korea) can secure the certificate first;
• Class III/IV products without international certificates: start standard registration now (current timeline 4-8 months); obtaining the certificate before or during 2027 both work; renewals will be updated to the new rules;
• Large IVD families: file now and set up the one-certificate-many-models architecture first (the combined-holding logic of up to 100 models works under both frameworks);
• General principle: whatever the route, Spanish technical documentation, ISO 13485, the GS1 barcode system and clinical/IVD performance data never go out of date – build the dossier to a “reusable evidence” standard and neither the old nor the new framework will penalize you;
• Tracking points: ARCSA must publish the accompanying operating guidance before the new regulation takes effect (before 2027-01-28); unresolved issues such as the standard-route timelines and the boundary for low-risk products will be settled by that guidance.

Q28. What is the market entry roadmap for Chinese manufacturers in Ecuador?

In order of priority, seven steps:

1. Classification first: self-assess under I/II/III/IV (TGA/ANVISA conclusions can be reused) and pre-confirm borderline products – note that it is not Colombia’s Class IIa/IIb system;

2. Evidence inventory: products with FDA/CE go in the first batch via the simplified route; products without international certificates budget for the longest timeline under the standard route;

3. Lock the holding structure: local Titular plus POA (apostilled) plus written exit clauses, or adopt a neutral holding structure; simultaneously confirm the validity of the holder’s BPADT and operating permit;

4. HS code upfront: declare the customs code at registration and calculate the tax burden after FTA tariff reductions (IVA 15% + FODINFA 0.5% + ad valorem duty + ISD 5%);

5. Register in batches: Class I/II first to generate cash flow, with Class III/IV prepared in parallel; package IVDs by family;

6. Compliance calendar: start renewals 6 months before expiry, plus a technovigilance response mechanism, plus final label submission within 1 year (NDM017), plus GS1 traceability readiness;

7. Andean synergy: the same dossier can be reused for Colombia (INVIMA) and Peru (DIGEMID), diluting regional compliance costs – but note that the classification systems, validity periods and holding rules of the three countries are each independent; do not mix them up.

Official fee amounts, review timelines and transitional arrangements are subject to ARCSA’s current official publications. This article is shared as industry information and does not constitute legal advice. For specific projects, rely on the latest official guidance and assessments by professional institutions.